

01-18-02

UTILITY PATENT APPLICATION

TRANSMITTAL

Nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

P31005C6

First Named Inventor

Browne, et al.

1000 U.S. PTO
10/05/2002A
01/16/02

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EL808219584US DATE OF DEPOSIT: 16 JANUARY 2002

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service

Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:

Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.


NAME OF PERSON MAILING PAPER OR FEE

TYPE OR PRINT)

Elsa Matos

SIGNATURE

Elsa Matos

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		7. <input checked="" type="checkbox"/> The Title of the Invention: NOVEL COMPOUNDS		
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u>		8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>09/200,324</u> , filed <u>25 November 1998</u> as the computer-readable form for the instant application. (37 CFR 1.821(e))		
<input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$740.00 Total Claims 16 - 20 = 0 x \$18 \$ 0.00 Independent Claims 1 - 3 = 0 x \$84 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$280 TOTAL FILING FEE \$740.00		9. <input type="checkbox"/> ACCOMPANYING APPLICATION PARTS a. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) b. <input checked="" type="checkbox"/> PTO-1449 c. <input checked="" type="checkbox"/> Copies of all IDS Citations		
<input type="checkbox"/> Cancel in this application original claims <u>_to_</u> of the prior application before calculating the filing fee.		10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))		
<input checked="" type="checkbox"/> Charge \$740.00 to the above indicated Deposit Account.		11. <input checked="" type="checkbox"/> Prior Application is Assigned to: <u>SmithKline Beecham Corporation</u> and <u>SmithKline Beecham p.l.c.</u> <i>(for continuation/divisional with Box 17a completed)</i>		
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>31</u>	12. <input type="checkbox"/> Preliminary Amendment [Total Pages]			
3b. <input type="checkbox"/> Abstract on a separate sheet [Total Pages]	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>			
4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] _____	14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>			
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17a completed)</i> c. <input type="checkbox"/> Unsigned Declaration <i>[Note Box 6 below]</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	15. <input type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. _____ filed _____ A PTO-1449 listing the references is enclosed.			
6. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	16. <input type="checkbox"/> Other: _____			
17. <input type="checkbox"/> Priority Information, check appropriate box and supply the requisite information				
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>09/599,074</u> filed 22 June 2000.				
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. _____ filed _____.				
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. <u>09/599,074</u> filed 22 June 2000 , which is a continuation of application Serial No. <u>09/200,324</u> filed 25 November 1998 , now abandoned, which is a continuation of application Serial No. <u>09/027,388</u> filed 20 February 1998 , now abandoned, which is a continuation of application Serial No. <u>08/468,296</u> filed 06 June 1995 , now abandoned, which claims priority from U.K. Application <u>9415379.8</u> , filed 19 July 1994 .				
Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Signature Name	Respectfully Submitted,  Kirk Baumeister	
Telephone	(610) 270-5096	Fax	(610) 270-5073	Registration No. 33,833



20462

PATENT TRADEMARK OFFICE